<div>
  <ul>
    <li>
      <p>
        In its Q2 2023 financial and business results for the period ended September 30, 2022, Vancouver-based psychedelic company Braxia Scientific reported revenue of USD 0.46 million, up by 18% YoY. This was primarily driven by its clinic's segment offering ketamine treatments (up 34.5% YoY).&nbsp;
      </p>
    </li>
    <li>
      <p>
        Braxia highlighted a few recent milestones, including 1) entering the US market through the acquisition of 
        <a href="https://sp-edge.com/updates/12117">
          KetaMD
        </a>
        , a telemedicine company offering at-home ketamine treatments, and launching its pilot platform in Florida; 2) completing the construction of its new clinic in Ottawa and progressing with its new flagship clinic in Toronto; 3) setting up three clinics to provide psilocybin-assisted therapy for patients following the approval from Health Canada&rsquo;s Special Access Program; and 4) progressing the Phase II clinical trial (launched in November 2021) of its psilocybin-based therapy and expecting to complete the trial by May 2023.
      </p>
    </li>
    <li>
      <p>
        For the upcoming quarters, the company put forth some plans including 1) initiating additional psilocybin-assisted clinical trials in the coming months; and 2) exploring funding and partnership options for its expansion initiatives. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.prnewswire.com/news-releases/braxia-scientific-reports-q2-2023-financial-results-focused-on-growing-clinic-and-telemedicine-delivery-of-novel-mental-health-treatments-in-north-america-301689579.html">
      PR Newswire
    </a>
  </p>
</div>


Psychedelic Medicine

Braxia Scientific provides business update for Q2 FY2023; focuses on clinic expansion and telemedicine

Braxia Scientific provides business update following KetaMD acquisition

All Updates

Braxia Scientific provides business update for Q2 FY2023; focuses on clinic expansion and telemedicine

Braxia Scientific provides business update following KetaMD acquisition

Braxia Scientific acquires KetaMD; enters US market

Braxia Scientific to raise CAD 3 million via private placement

Braxia Scientific releases Q2 2022 financial results

Braxia Scientific sees significant reduction in losses during Q1 2022

Braxia Scientific releases FY2021 financial results